Breast cancer vaccination comes to age: impacts of bioinformatics

Abstract

Introduction: Breast cancer, as one of the major causes of cancer death among women, is the central focus of this study. The recent advances in the development and application of computational tools and bioinformatics in the field of immunotherapy of malignancies such as breast cancer have emerged the new dominion of immunoinformatics, and therefore, next generation of immunomedicines . Methods: Having reviewed the most recent works on the applications of computational tools, we provide comprehensive insights into the breast cancer incidence and its leading causes as well as immunotherapy approaches and the future trends. Furthermore, we discuss the impacts of bioinformatics on different stages of vaccine design for the breast cancer, which can be used to produce much more efficient vaccines through a rationalized time- and cost-effective in silico approaches prior to conducting costly experiments. Results: The tools can be significantly used for designing the immune system-modulating drugs and vaccines based on in silico approaches prior to in vitro and in vivo experimental evaluations. Application of immunoinformatics in the cancer immunotherapy has shown its success in the pre-clinical models. This success returns back to the impacts of several powerful computational approaches developed during the last decade. Conclusion: Despite the invention of a number of vaccines for the cancer immunotherapy, more computational and clinical trials are required to design much more efficient vaccines against various malignancies, including breast cancer.

Upregulation of human endogenous retrovirus-K (HML-2) mRNAs in hepatoblastoma: Identification of potential new immunotherapeutic targets and biomarkers

“…With the advancement in massive parallel sequencing technologies, which have now generated numerous RNA-seq datasets of multiple tumor types, bioinformatic techniques that allow analysis of these powerful datasets are becoming increasingly necessary [73]. HERV-K proviruses pose a difficult challenge for computational analysis of RNA-seq data as these regions are poorly annotated and constitute repeat elements making unique alignment of RNA-seq reads difficult [49].…”

miR‑187‑3p increases gemcitabine sensitivity in breast cancer cells by targeting FGF9 expression

“…Breast cancer is the most commonly diagnosed type of cancer in women, with its incidence ranking the highest among all malignancies ( 27 ). Accumulating evidence has demonstrated that targeted therapies offer superior therapeutic efficacy compared with conventional approaches ( 28 ).…”

HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development

“…Here the tumor cell lysates from a patient's own tumor antigens are exploited to develop an effective immune response. However, the major disadvantages of allogeneic tumor cell vaccine (ATCV) is the inherent poor immunogenicity of tumor cells and inconsistency of the production method (Parvizpour et al 2018). In addition, due to the presence of endogenous cellular antigens, an autoimmune reaction is possible (Al-Awadhi et al 2018;Kurtz et al 2014).…”